CMV resistant to ganciclovir and maribavir in a heart-transplanted Patient: A case report
Resistant/refractory Cytomegalovirus (CMV) infection is an important threat in the management of solid organ transplant recipients, often associated with poor outcomes. We describe the case of a heart-transplanted patient who developed primary CMV infection with fever and subsequent appearance of resistance to ganciclovir and maribavir during antiviral treatment, and with important toxicity due to foscarnet. The outcome was good with reduced-dose continuous infusion of foscarnet. Further research is needed to improve the management of difficult-to-treat CMV infection.
Authors
- Eleonora Cimini
- Gabriella Rozera
- Pierangelo Chinello (ORCID: https://orcid.org/0000-0002-7341-9000)
- Fabrizio Maggi (ORCID: https://orcid.org/0000-0001-7489-5271)
- Samir Al Moghazi
- Stefania Cicalini (ORCID: https://orcid.org/0000-0002-0754-6917)
- Simone Topino
- Fabio Sbaraglia (ORCID: https://orcid.org/0000-0001-9565-264X)
- Alessandro Capone (ORCID: https://orcid.org/0000-0002-9964-1195)
- Elisabetta Lazzari (ORCID: https://orcid.org/0009-0008-0558-0610)
- Isabella Abbate (ORCID: https://orcid.org/0000-0002-4154-2434)
- Martina Reuca
Institutions
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
- Center for Prevention and Treatment of Infections (US)
- IRCCS San Camillo Hospital (IT)
Publication Details
- Journal
- Heliyon
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.heliyon.2025.e43904
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00